Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia (May).

Posted by rob on March 30, 2009 under Uncategorized | Comments are off for this article

CONCLUSIONS: Dasatinib 100 mg once daily has a more favorable risk to benefit assessment compared with the previous 70 mg twice-daily regimen and is now the recommended schedule for patients with CP CML.
PMID: 19336654 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)